Parabilis Medicines
PublicParabilis Medicines is now publicly traded
The data on this page reflects Parabilis Medicines's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jun 9, 2026
Last Round
Series F
Jan 8, 2026
Total Funding Raised
$1.57B
Company Overview
Parabilis Medicines is a clinical-stage biopharmaceutical company that develops stabilized helical peptide therapeutics, known as Helicons, to target undruggable protein-protein interactions in oncology.
AI Layer
Application
Keywords
Parabilis Medicines Comparables
Compare Parabilis Medicines with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| WntRx Pharmaceuticals | 77% | |
| Sapience Therapeutics | 77% | |
| Circle Pharma | 76% |
Parabilis Medicines Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jun 9, 2026 | ||||
| Series F | Jan 8, 2026 | ||||
| Series E | Mar 1, 2024 | ||||
| Series D | Nov 21, 2022 | ||||
| Series C | Mar 1, 2021 | ||||
Series B | May 16, 2018 |
Key People
Founding team and executive leadership
Parabilis Medicines Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Soleus Capital | Series F |
| Janus Henderson Group | Series F |
| Horizons Ventures | Series B |
| Boyu Capital | Series B |
| RA Capital Management | Series E, Series F |
| Farallon Capital Management | Series F, Series C, Series E, Series D |
| Sixty Degree Capital | Series F, Series E |
Parabilis Medicines Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request access